查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1211054

全球 T 细胞淋巴瘤市场规模调查和预测：按淋巴瘤类型、治疗类型和地区分析，2022-2029 年

Global T-Cell Lymphoma Market Size study & Forecast, by Lymphoma Type, Therapy Type and Regional Analysis, 2022-2029
出版日期: | 出版商: Bizwit Research & Consulting LLP | 英文 | 商品交期: 2-3个工作天内

价格

2021 年全球 T 细胞淋巴瘤市场价值约为 15.8889 亿美元，预计在 2022-2029 年预测期内将以超过 8.25% 的健康增长率增长。

T 细胞淋巴瘤是一种在称为 T 细胞的免疫系统中发展的血癌。 由于淋巴癌发病率上升、T 细胞淋巴瘤特异性疗法的进步以及自身免疫性疾病导致的淋巴瘤风险等因素，T 细胞淋巴瘤市场正在扩大。 该市场由强生公司（Janssen Pharmaceuticals, Inc.）、诺华公司、百时美施贵宝公司、默克公司和 F. Hoffman Brothers, Inc. 主导。 Inc. 和 F. Hoffmann-La Roche Ltd.

由于血癌的增加，T 细胞淋巴瘤的患病率也在增加。 根据白血病和淋巴瘤协会 (R) (LLS) 的数据，美国大约三分之一的人被诊断出患有白血病、淋巴瘤或骨髓瘤。 预计到 2021 年，美国将有 186,400 人被诊断出患有白血病、淋巴瘤和骨髓瘤。 在美国 2021 年新诊断的 1,898,160 例癌症中，预计将有 9.8% 的白血病、淋巴瘤和骨髓瘤新病例。 此外，高价产品和免疫检查点抑製剂的采用，以及多种新型治疗剂的推出以及商业产品的扩展标籤，预计将在未来几年增加这一市场机会。 然而，高昂的治疗成本和治疗药物的不良副作用阻碍了整个 2022-2029 年预测期内的市场增长。

全球 T 细胞淋巴瘤市场研究中考虑的主要区域是亚太地区、北美、欧洲、拉丁美洲和世界其他地区。 由于品牌产品的主导地位和该地区疾病流行率的增加，北美在收入方面占据了市场主导地位。 根据Globocan 2020报告，2020年加拿大发生非霍奇金淋巴瘤8506例，死亡313例。 预计这将增加该国 T 细胞淋巴瘤的发病率。 由于疾病增多、免疫系统薄弱、网民健康意识增强以及政府和非营利组织积极参与市场空间等因素，预计亚太地区在预测期内将以最高复合年增长率增长。

这项研究的目的是定义近年来各个细分市场和国家的市场规模，并预测它们在未来几年的价值。 该报告旨在捕捉被调查国家工业的定性和定量方面的情况。

它还提供了关键方面的详细信息，例如决定市场未来增长的驱动因素和挑战。 此外，它还包含供利益相关者投资的微观市场潜在机会，以及对主要参与者的竞争格局和产品供应的深入分析。

内容

第 1 章执行摘要

  • 市场概况
  • 2019-2029 年各细分市场的全球市场估计和预测
    • T 细胞淋巴瘤市场：按地区划分，2019-2029 年
    • T 细胞淋巴瘤市场（按淋巴瘤类型）：2019-2029
    • 按治疗类型划分的 T 细胞淋巴瘤市场：2019 年至 2029 年
  • 主要趋势
  • 调查方法
  • 调查先决条件

第 2 章 T 细胞淋巴瘤的全球市场定义和范围

  • 调查的目的
  • 市场定义和范围
    • 调查范围
    • 工业发展
  • 调查年份
  • 货币兑换率

第 3 章全球 T 细胞淋巴瘤市场动态

  • T 细胞淋巴瘤的市场影响分析 (2019-2029)
    • 市场驱动力
      • 淋巴癌发病率上升
      • T 细胞淋巴瘤特异性治疗的进展
      • 自身免疫性疾病导致的淋巴瘤风险
    • 市场挑战
      • 高昂的治疗费用
      • 治疗剂的有害副作用
    • 市场机会
      • 采用高端产品和免疫检查点抑製剂
      • 推出几种新的治疗药物并扩大现有产品的适应症

第 4 章全球 T 细胞淋巴瘤市场行业分析

  • 波特 5 力模型
    • 供应商的议价能力
    • 买家的议价能力
    • 新进入者的威胁
    • 替代品的威胁
    • 竞争公司之间的敌对关係
  • 波特 5 力模型的未来方法 (2019-2029)
  • 害虫分析
    • 政治
    • 经济的
    • 社交
    • 技术
  • 顶级投资机会
  • 关键成功策略
  • 行业专家的展望
  • 分析师的结论和建议

第 5 章风险评估：COVID-19 的影响

  • 评估 COVID-19 对行业的总体影响
  • COVID-19 之前和 COVID-19 之后的市场情景

第 6 章全球 T 细胞淋巴瘤市场，按淋巴瘤类型

  • 市场概况
  • T 细胞淋巴瘤的全球市场：按淋巴瘤类型进行性能潜力分析
  • 2019-2029 年全球 T 细胞淋巴瘤市场，按淋巴瘤类型估计和预测
  • T 细胞淋巴瘤市场，细分市场分析
    • 外周T细胞淋巴瘤
    • T 细胞淋巴母细胞淋巴瘤

第 7 章：全球 T 细胞淋巴瘤市场：按治疗类型分类

  • 市场概况
  • 全球 T 细胞淋巴瘤市场：按治疗类型、性能潜力分析
  • 2019-2029 年全球 T 细胞淋巴瘤市场，按治疗类型估计和预测
  • T 细胞淋巴瘤市场，细分市场分析
    • 放射治疗
    • 化疗
    • 免疫疗法
    • 干细胞移植
    • 其他类型的治疗

第 8 章全球 T 细胞淋巴瘤市场：区域分析

  • T 细胞淋巴瘤市场，按地区划分的市场概况
  • 北美
    • 美国
      • 按淋巴瘤类型估计和预测，2019-2029
      • 2019-2029 年按治疗类型估算和预测
    • 加拿大
  • 欧洲 T 细胞淋巴瘤市场概况
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 意大利
    • 其他欧洲地区
  • 亚太地区 T 细胞淋巴瘤市场概况
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 韩国
    • 其他亚太地区
  • 拉丁美洲 T 细胞淋巴瘤市场概况
    • 巴西
    • 墨西哥
    • 其他拉丁美洲地区
  • 世界其他地方

第 9 章衝突信息

  • 顶级市场策略
  • 公司简介
    • Genmab AS
      • 主要信息
      • 概览
      • 财务信息（取决于数据可用性）
      • 产品概览
      • 近期趋势
    • Johnson & Johnson（Janssen Pharmaceuticals Inc.）
    • Mundipharma International, Limited
    • Bristol-Myers Squibb Company
    • Autolus Therapeutics PLC
    • Acrotech Biopharma, Inc.
    • Macopharma
    • Merck & Co. Inc.
    • F. Hoffmann-La Roche Ltd
    • Novartis AG

第 10 章研究过程

  • 研究过程
    • 数据挖掘
    • 分析
    • 市场评估
    • 验证
    • 出版
  • 调查属性
  • 调查先决条件

Global T-Cell Lymphoma Market is valued at approximately USD 1588.89 million in 2021 and is anticipated to grow with a healthy growth rate of more than 8.25% over the forecast period 2022-2029. T-Cell Lymphoma is a type of blood cancer which arises in an immune system named as T-cell. The T-Cell Lymphoma market is expanding because of factors such as rise in lymphoma cancer incidence, advancements in T-cell lymphoma-specific therapies and the risk of lymphoma due to autoimmune disorders. This market is dominated by Johnson & Johnson (Janssen Pharmaceuticals Inc.), Novartis AG, Bristol Myers Squibb Company, Merck & Co. Inc., and F. Hoffmann-La Roche Ltd.

The rising number of blood cancer has increased the prevalence of T-cell lymphoma. As per the Leukemia & Lymphoma Society® (LLS), about one in three people in the United States is diagnosed with leukaemia, lymphoma, or myeloma. In 2021, a total of 186,400 people in the United States are expected to be diagnosed with leukaemia, lymphoma, or myeloma. New cases of leukaemia, lymphoma, and myeloma are expected to account for 9.8% of the estimated 1,898,160 new cancer cases diagnosed in the United States in 2021. Furthermore, the uptake of premium-priced products and immune checkpoint inhibitors as well as the launch of several novel therapies with label extensions of commercialized products are expected to increase the opportunity for this market in the forthcoming years. However, the high cost of Treatment and Adverse Side Effects of Therapies stifles market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global T-Cell Lymphoma Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America dominated the market in terms of revenue, owing to the dominance of branded products and the region's increasing disease prevalence. According to the Globocan 2020 report, 8,506 cases of non-Hodgkin's lymphoma occurred in Canada in 2020, with 313 deaths. This is expected to increase the incidence of T-cell lymphoma in the country. Asia Pacific is expected to grow with the highest CAGR during the forecast period, owing to factors such as rising disease, weak immune systems, rising health awareness among the netizen and active participation of government and nonprofit organizations in the market space.

Major market players included in this report are:

Genmab AS

Johnson & Johnson (Janssen Pharmaceuticals Inc.)

Mundipharma International, Limited

Bristol-Myers Squibb Company

Autolus Therapeutics PLC

Acrotech Biopharma, Inc.

Macopharma

Merck & Co. Inc.

F. Hoffmann-La Roche Ltd

Novartis AG

Recent Developments in the Market:

  • In September 2021, Soligenix Inc. announced that the U.S. Food and Drug Administration's (FDA) Office of Orphan Drug Development granted orphan drug designation to hypericin for the treatment of T-cell lymphoma (CTCL).
  • In December 2020, the FDA approved her new drug application for LB1901. It's an investigational chimeric antigen receptor T-cell therapy for the treatment of adults with relapsed or refractory Cutaneous T-cell lymphoma.
  • In July 2020, miRagen Therapeutics Inc. announced that the Food and Drug Administration (FDA) granted orphan drug designation to cobomarsen for the treatment of her T-cell lymphoma. Cobomarsen is being developed by miRagen in two clinical programs for the treatment of different types of T-cell lymphoma, including a Phase 2 trial in cutaneous T-cell lymphoma (CTCL) and a Phase 1 trial in adult T-cell lymphoma. inhibitor (ATLL) Ultraviolet.

Global T-Cell Lymphoma Market Report Scope:

Historical Data: 2019-2020-2021

Base Year for Estimation: 2021

Forecast period: 2022-2029

Report Coverage: Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends

Segments Covered: Lymphoma Type, Therapy Type, Region

Regional Scope: North America; Europe; Asia Pacific; Latin America; Rest of the World

Customization Scope: Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Lymphoma Type:

Peripheral T-cell Lymphoma

T-cell Lymphoblastic Lymphoma

By Therapy Type:

Radiotherapy

Chemotherapy

Immunotherapy

Stem Cell Transplantation

Other Types of Therapies

By Region:

North America

U.S.

Canada

Europe

UK

Germany

France

Spain

Italy

ROE

Asia Pacific

China

India

Japan

Australia

South Korea

RoAPAC

Latin America

Brazil

Mexico

RoLA

Rest of the World

Table of Contents

Chapter 1. Executive Summary

  • 1.1. Market Snapshot
  • 1.2. Global & Segmental Market Estimates & Forecasts, 2019-2029 (USD Million)
    • 1.2.1. T-Cell Lymphoma Market, by Region, 2019-2029 (USD Million)
    • 1.2.2. T-Cell Lymphoma Market, by Lymphoma Type, 2019-2029 (USD Million)
    • 1.2.3. T-Cell Lymphoma Market, by Therapy Type, 2019-2029 (USD Million)
  • 1.3. Key Trends
  • 1.4. Estimation Methodology
  • 1.5. Research Assumption

Chapter 2. Global T-Cell Lymphoma Market Definition and Scope

  • 2.1. Objective of the Study
  • 2.2. Market Definition & Scope
    • 2.2.1. Scope of the Study
    • 2.2.2. Industry Evolution
  • 2.3. Years Considered for the Study
  • 2.4. Currency Conversion Rates

Chapter 3. Global T-Cell Lymphoma Market Dynamics

  • 3.1. T-Cell Lymphoma Market Impact Analysis (2019-2029)
    • 3.1.1. Market Drivers
      • 3.1.1.1. Rise in Lymphoma Cancer Incidence
      • 3.1.1.2. Advancements in T-cell Lymphoma-specific Therapies
      • 3.1.1.3. Risk of Lymphoma due to Autoimmune Disorders
    • 3.1.2. Market Challenges
      • 3.1.2.1. High Cost of Treatment
      • 3.1.2.2. Adverse Side Effects of Therapies
    • 3.1.3. Market Opportunities
      • 3.1.3.1. Uptake Of Premium-Priced Products and Immune Checkpoint Inhibitors
      • 3.1.3.2. Launch Of Several Novel Therapies with Label Extension of Commercialized Products

Chapter 4. Global T-Cell Lymphoma Market Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
  • 4.2. Futuristic Approach to Porter's 5 Force Model (2019-2029)
  • 4.3. PEST Analysis
    • 4.3.1. Political
    • 4.3.2. Economical
    • 4.3.3. Social
    • 4.3.4. Technological
  • 4.4. Top investment opportunity
  • 4.5. Top winning strategies
  • 4.6. Industry Experts Prospective
  • 4.7. Analyst Recommendation & Conclusion

Chapter 5. Risk Assessment: COVID-19 Impact

  • 5.1. Assessment of the overall impact of COVID-19 on the industry
  • 5.2. Pre COVID-19 and post COVID-19 Market scenario

Chapter 6. Global T-Cell Lymphoma Market, by Lymphoma Type

  • 6.1. Market Snapshot
  • 6.2. Global T-Cell Lymphoma Market by Lymphoma Type, Performance - Potential Analysis
  • 6.3. Global T-Cell Lymphoma Market Estimates & Forecasts by Lymphoma Type 2019-2029 (USD Million)
  • 6.4. T-Cell Lymphoma Market, Sub Segment Analysis
    • 6.4.1. Peripheral T-cell Lymphoma
    • 6.4.2. T-cell Lymphoblastic Lymphoma

Chapter 7. Global T-Cell Lymphoma Market, by Therapy Type

  • 7.1. Market Snapshot
  • 7.2. Global T-Cell Lymphoma Market by Therapy Type, Performance - Potential Analysis
  • 7.3. Global T-Cell Lymphoma Market Estimates & Forecasts by Therapy Type 2019-2029 (USD Million)
  • 7.4. T-Cell Lymphoma Market, Sub Segment Analysis
    • 7.4.1. Radiotherapy
    • 7.4.2. Chemotherapy
    • 7.4.3. Immunotherapy
    • 7.4.4. Stem Cell Transplantation
    • 7.4.5. Other Types of Therapies

Chapter 8. Global T-Cell Lymphoma Market, Regional Analysis

  • 8.1. T-Cell Lymphoma Market, Regional Market Snapshot
  • 8.2. North America T-Cell Lymphoma Market
    • 8.2.1. U.S. T-Cell Lymphoma Market
      • 8.2.1.1. Lymphoma Type breakdown estimates & forecasts, 2019-2029
      • 8.2.1.2. Therapy Type breakdown estimates & forecasts, 2019-2029
    • 8.2.2. Canada T-Cell Lymphoma Market
  • 8.3. Europe T-Cell Lymphoma Market Snapshot
    • 8.3.1. U.K. T-Cell Lymphoma Market
    • 8.3.2. Germany T-Cell Lymphoma Market
    • 8.3.3. France T-Cell Lymphoma Market
    • 8.3.4. Spain T-Cell Lymphoma Market
    • 8.3.5. Italy T-Cell Lymphoma Market
    • 8.3.6. Rest of Europe T-Cell Lymphoma Market
  • 8.4. Asia-Pacific T-Cell Lymphoma Market Snapshot
    • 8.4.1. China T-Cell Lymphoma Market
    • 8.4.2. India T-Cell Lymphoma Market
    • 8.4.3. Japan T-Cell Lymphoma Market
    • 8.4.4. Australia T-Cell Lymphoma Market
    • 8.4.5. South Korea T-Cell Lymphoma Market
    • 8.4.6. Rest of Asia Pacific T-Cell Lymphoma Market
  • 8.5. Latin America T-Cell Lymphoma Market Snapshot
    • 8.5.1. Brazil T-Cell Lymphoma Market
    • 8.5.2. Mexico T-Cell Lymphoma Market
    • 8.5.3. Rest of Latin America T-Cell Lymphoma Market
  • 8.6. Rest of The World T-Cell Lymphoma Market

Chapter 9. Competitive Intelligence

  • 9.1. Top Market Strategies
  • 9.2. Company Profiles
    • 9.2.1. Genmab AS
      • 9.2.1.1. Key Information
      • 9.2.1.2. Overview
      • 9.2.1.3. Financial (Subject to Data Availability)
      • 9.2.1.4. Product Summary
      • 9.2.1.5. Recent Developments
    • 9.2.2. Johnson & Johnson (Janssen Pharmaceuticals Inc.)
    • 9.2.3. Mundipharma International, Limited
    • 9.2.4. Bristol-Myers Squibb Company
    • 9.2.5. Autolus Therapeutics PLC
    • 9.2.6. Acrotech Biopharma, Inc.
    • 9.2.7. Macopharma
    • 9.2.8. Merck & Co. Inc.
    • 9.2.9. F. Hoffmann-La Roche Ltd
    • 9.2.10. Novartis AG

Chapter 10. Research Process

  • 10.1. Research Process
    • 10.1.1. Data Mining
    • 10.1.2. Analysis
    • 10.1.3. Market Estimation
    • 10.1.4. Validation
    • 10.1.5. Publishing
  • 10.2. Research Attributes
  • 10.3. Research Assumption

LIST OF TABLES

  • TABLE 1. Global T-Cell Lymphoma Market, report scope
  • TABLE 2. Global T-Cell Lymphoma Market estimates & forecasts by Region 2019-2029 (USD Million)
  • TABLE 3. Global T-Cell Lymphoma Market estimates & forecasts by Lymphoma Type 2019-2029 (USD Million)
  • TABLE 4. Global T-Cell Lymphoma Market estimates & forecasts by Therapy Type 2019-2029 (USD Million)
  • TABLE 5. Global T-Cell Lymphoma Market by segment, estimates & forecasts, 2019-2029 (USD Million)
  • TABLE 6. Global T-Cell Lymphoma Market by region, estimates & forecasts, 2019-2029 (USD Million)
  • TABLE 7. Global T-Cell Lymphoma Market by segment, estimates & forecasts, 2019-2029 (USD Million)
  • TABLE 8. Global T-Cell Lymphoma Market by region, estimates & forecasts, 2019-2029 (USD Million)
  • TABLE 9. Global T-Cell Lymphoma Market by segment, estimates & forecasts, 2019-2029 (USD Million)
  • TABLE 10. Global T-Cell Lymphoma Market by region, estimates & forecasts, 2019-2029 (USD Million)
  • TABLE 11. Global T-Cell Lymphoma Market by segment, estimates & forecasts, 2019-2029 (USD Million)
  • TABLE 12. Global T-Cell Lymphoma Market by region, estimates & forecasts, 2019-2029 (USD Million)
  • TABLE 13. Global T-Cell Lymphoma Market by segment, estimates & forecasts, 2019-2029 (USD Million)
  • TABLE 14. Global T-Cell Lymphoma Market by region, estimates & forecasts, 2019-2029 (USD Million)
  • TABLE 15. U.S. T-Cell Lymphoma Market estimates & forecasts, 2019-2029 (USD Million)
  • TABLE 16. U.S. T-Cell Lymphoma Market estimates & forecasts by segment 2019-2029 (USD Million)
  • TABLE 17. U.S. T-Cell Lymphoma Market estimates & forecasts by segment 2019-2029 (USD Million)
  • TABLE 18. Canada T-Cell Lymphoma Market estimates & forecasts, 2019-2029 (USD Million)
  • TABLE 19. Canada T-Cell Lymphoma Market estimates & forecasts by segment 2019-2029 (USD Million)
  • TABLE 20. Canada T-Cell Lymphoma Market estimates & forecasts by segment 2019-2029 (USD Million)
  • TABLE 21. UK T-Cell Lymphoma Market estimates & forecasts, 2019-2029 (USD Million)
  • TABLE 22. UK T-Cell Lymphoma Market estimates & forecasts by segment 2019-2029 (USD Million)
  • TABLE 23. UK T-Cell Lymphoma Market estimates & forecasts by segment 2019-2029 (USD Million)
  • TABLE 24. Germany T-Cell Lymphoma Market estimates & forecasts, 2019-2029 (USD Million)
  • TABLE 25. Germany T-Cell Lymphoma Market estimates & forecasts by segment 2019-2029 (USD Million)
  • TABLE 26. Germany T-Cell Lymphoma Market estimates & forecasts by segment 2019-2029 (USD Million)
  • TABLE 27. France T-Cell Lymphoma Market estimates & forecasts, 2019-2029 (USD Million)
  • TABLE 28. France T-Cell Lymphoma Market estimates & forecasts by segment 2019-2029 (USD Million)
  • TABLE 29. France T-Cell Lymphoma Market estimates & forecasts by segment 2019-2029 (USD Million)
  • TABLE 30. Italy T-Cell Lymphoma Market estimates & forecasts, 2019-2029 (USD Million)
  • TABLE 31. Italy T-Cell Lymphoma Market estimates & forecasts by segment 2019-2029 (USD Million)
  • TABLE 32. Italy T-Cell Lymphoma Market estimates & forecasts by segment 2019-2029 (USD Million)
  • TABLE 33. Spain T-Cell Lymphoma Market estimates & forecasts, 2019-2029 (USD Million)
  • TABLE 34. Spain T-Cell Lymphoma Market estimates & forecasts by segment 2019-2029 (USD Million)
  • TABLE 35. Spain T-Cell Lymphoma Market estimates & forecasts by segment 2019-2029 (USD Million)
  • TABLE 36. RoE T-Cell Lymphoma Market estimates & forecasts, 2019-2029 (USD Million)
  • TABLE 37. RoE T-Cell Lymphoma Market estimates & forecasts by segment 2019-2029 (USD Million)
  • TABLE 38. RoE T-Cell Lymphoma Market estimates & forecasts by segment 2019-2029 (USD Million)
  • TABLE 39. China T-Cell Lymphoma Market estimates & forecasts, 2019-2029 (USD Million)
  • TABLE 40. China T-Cell Lymphoma Market estimates & forecasts by segment 2019-2029 (USD Million)
  • TABLE 41. China T-Cell Lymphoma Market estimates & forecasts by segment 2019-2029 (USD Million)
  • TABLE 42. India T-Cell Lymphoma Market estimates & forecasts, 2019-2029 (USD Million)
  • TABLE 43. India T-Cell Lymphoma Market estimates & forecasts by segment 2019-2029 (USD Million)
  • TABLE 44. India T-Cell Lymphoma Market estimates & forecasts by segment 2019-2029 (USD Million)
  • TABLE 45. Japan T-Cell Lymphoma Market estimates & forecasts, 2019-2029 (USD Million)
  • TABLE 46. Japan T-Cell Lymphoma Market estimates & forecasts by segment 2019-2029 (USD Million)
  • TABLE 47. Japan T-Cell Lymphoma Market estimates & forecasts by segment 2019-2029 (USD Million)
  • TABLE 48. South Korea T-Cell Lymphoma Market estimates & forecasts, 2019-2029 (USD Million)
  • TABLE 49. South Korea T-Cell Lymphoma Market estimates & forecasts by segment 2019-2029 (USD Million)
  • TABLE 50. South Korea T-Cell Lymphoma Market estimates & forecasts by segment 2019-2029 (USD Million)
  • TABLE 51. Australia T-Cell Lymphoma Market estimates & forecasts, 2019-2029 (USD Million)
  • TABLE 52. Australia T-Cell Lymphoma Market estimates & forecasts by segment 2019-2029 (USD Million)
  • TABLE 53. Australia T-Cell Lymphoma Market estimates & forecasts by segment 2019-2029 (USD Million)
  • TABLE 54. RoAPAC T-Cell Lymphoma Market estimates & forecasts, 2019-2029 (USD Million)
  • TABLE 55. RoAPAC T-Cell Lymphoma Market estimates & forecasts by segment 2019-2029 (USD Million)
  • TABLE 56. RoAPAC T-Cell Lymphoma Market estimates & forecasts by segment 2019-2029 (USD Million)
  • TABLE 57. Brazil T-Cell Lymphoma Market estimates & forecasts, 2019-2029 (USD Million)
  • TABLE 58. Brazil T-Cell Lymphoma Market estimates & forecasts by segment 2019-2029 (USD Million)
  • TABLE 59. Brazil T-Cell Lymphoma Market estimates & forecasts by segment 2019-2029 (USD Million)
  • TABLE 60. Mexico T-Cell Lymphoma Market estimates & forecasts, 2019-2029 (USD Million)
  • TABLE 61. Mexico T-Cell Lymphoma Market estimates & forecasts by segment 2019-2029 (USD Million)
  • TABLE 62. Mexico T-Cell Lymphoma Market estimates & forecasts by segment 2019-2029 (USD Million)
  • TABLE 63. RoLA T-Cell Lymphoma Market estimates & forecasts, 2019-2029 (USD Million)
  • TABLE 64. RoLA T-Cell Lymphoma Market estimates & forecasts by segment 2019-2029 (USD Million)
  • TABLE 65. RoLA T-Cell Lymphoma Market estimates & forecasts by segment 2019-2029 (USD Million)
  • TABLE 66. Row T-Cell Lymphoma Market estimates & forecasts, 2019-2029 (USD Million)
  • TABLE 67. Row T-Cell Lymphoma Market estimates & forecasts by segment 2019-2029 (USD Million)
  • TABLE 68. Row T-Cell Lymphoma Market estimates & forecasts by segment 2019-2029 (USD Million)
  • TABLE 69. List of secondary sources, used in the study of global T-Cell Lymphoma Market
  • TABLE 70. List of primary sources, used in the study of global T-Cell Lymphoma Market
  • TABLE 71. Years considered for the study
  • TABLE 72. Exchange rates considered

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

LIST OF FIGURES

List of figures

  • FIG 1. Global T-Cell Lymphoma Market, research methodology
  • FIG 2. Global T-Cell Lymphoma Market, Market estimation techniques
  • FIG 3. Global Market size estimates & forecast methods
  • FIG 4. Global T-Cell Lymphoma Market, key trends 2021
  • FIG 5. Global T-Cell Lymphoma Market, growth prospects 2022-2029
  • FIG 6. Global T-Cell Lymphoma Market, porters 5 force model
  • FIG 7. Global T-Cell Lymphoma Market, pest analysis
  • FIG 8. Global T-Cell Lymphoma Market, value chain analysis
  • FIG 9. Global T-Cell Lymphoma Market by segment, 2019 & 2029 (USD Million)
  • FIG 10. Global T-Cell Lymphoma Market by segment, 2019 & 2029 (USD Million)
  • FIG 11. Global T-Cell Lymphoma Market by segment, 2019 & 2029 (USD Million)
  • FIG 12. Global T-Cell Lymphoma Market by segment, 2019 & 2029 (USD Million)
  • FIG 13. Global T-Cell Lymphoma Market by segment, 2019 & 2029 (USD Million)
  • FIG 14. Global T-Cell Lymphoma Market, regional snapshot 2019 & 2029
  • FIG 15. North America T-Cell Lymphoma Market 2019 & 2029 (USD Million)
  • FIG 16. Europe T-Cell Lymphoma Market 2019 & 2029 (USD Million)
  • FIG 17. Asia pacific T-Cell Lymphoma Market 2019 & 2029 (USD Million)
  • FIG 18. Latin America T-Cell Lymphoma Market 2019 & 2029 (USD Million)
  • FIG 19. Global T-Cell Lymphoma Market, company Market share analysis (2021)

List of tables and figures and dummy in nature, final lists may vary in the final deliverable